Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.61 USD
-1.82 (-6.64%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $25.58 -0.03 (-0.12%) 4:44 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BEAM 25.61 -1.82(-6.64%)
Will BEAM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
Other News for BEAM
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2024 Update
iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum
Interesting BEAM Put And Call Options For September 20th
Why Is Conn’s (CONN) Stock Down 36% Today?
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40